Investor Relations

Advanced therapies for the sports medicine and severe burn care markets

Investor Relations

Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Vericel to Present at the Leerink Partners Healthcare Crossroads Conference on Wednesday, May 29, 2024
CAMBRIDGE, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO and Joe Mara, CFO will participate in a fireside chat at the Leerink
View HTML
Toggle Summary Vericel Reports First Quarter 2024 Financial Results and Raises Full-Year 2024 Financial Guidance
Total Revenue Increased 25% to $51.3 Million Record First Quarter MACI Revenue of $40.2 Million and Burn Care Revenue Growth of 63% Adjusted EBITDA Growth of 325% Full-Year 2024 Revenue Guidance Raised to $238-$242 Million Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., May 08, 2024
View HTML
Toggle Summary Vericel to Report First-Quarter 2024 Financial Results on May 8, 2024
CAMBRIDGE, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its first-quarter 2024 financial results on Wednesday, May 8, 2024.
View HTML
Toggle Summary Vericel Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Full-Year 2024 Financial Guidance
Full-Year 2023 Total Revenue Growth of 20% to $197.5 Million, with Adjusted EBITDA Growth of 40% Fourth Quarter Total Revenue Growth of 23% to $65.0 Million, with Adjusted EBITDA Growth of 50% Fourth Quarter Gross Margin of 75% and Adjusted EBITDA Margin of 34% Full-Year 2024 Total Revenue Guidance
View HTML
Toggle Summary Vericel to Present at the TD Cowen 44th Annual Health Care Conference on Tuesday, March 5, 2024
CAMBRIDGE, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO and Joe Mara, CFO will participate in a fireside chat at the TD Cowen 44
View HTML
Toggle Summary Vericel to Report Fourth-Quarter and Full-Year 2023 Financial Results on February 29, 2024
CAMBRIDGE, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its fourth-quarter and full-year 2023 financial results on Thursday, February 29, 2024.
View HTML
Toggle Summary Vericel to Present at the Canaccord Genuity Musculoskeletal Conference on Monday, February 12, 2024
CAMBRIDGE, Mass., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO will present at the Canaccord Genuity Musculoskeletal Conference.
View HTML
Toggle Summary Vericel Announces Preliminary Full-Year and Fourth Quarter 2023 Financial Results
Full-Year Total Revenue Expected to be Approximately $197.5 Million, Representing 20% Growth, with Fourth Quarter Revenue Growth of 23% to $65 Million MACI Full-Year Revenue Expected to be Approximately $164.8 Million, Representing 25% Growth, with Fourth Quarter Revenue Growth of 22% to $56.7M
View HTML
Toggle Summary Vericel to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024
CAMBRIDGE, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO will present at the 42 nd Annual J.P. Morgan Healthcare Conference.
View HTML
Toggle Summary Vericel Reports Third Quarter 2023 Financial Results and Raises Full-Year 2023 Financial Guidance
Record Third Quarter Revenue of $45.6 Million, Representing 18% Growth versus Prior Year MACI Revenue Growth of 21% to $37.6 Million Full-Year 2023 Revenue Guidance Raised to $192.5-197.5 Million Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., Nov.
View HTML

Day High:
Day Low:
Volume:
on
Data Provided by Refinitiv. Minimum 15 minutes delayed.